Related stories
Merck Stops Blood Cancer Drug Trials After Risk Review
Merck stopped trials of a blood cancer drug after reviewing the risks.
M impact | EQUITY | Nov 17, 2026, 11:20 PM UTC
Salesforce has started cutting more jobs
Business Insider reports that Salesforce has started cutting jobs; the scope of the reductions is unclear.
M impact | EQUITY | Nov 17, 2026, 11:18 PM UTC
SeaStar Medical CFO Acquires 2,500 Shares for $2,124.50
M impact | EQUITY | Nov 17, 2026, 11:14 PM UTC
Vitalist Q2 revenue falls 92% on lower retail sales
Canada's Vitalist reported a 92% decline in Q2 revenue, citing lower retail sales.
M impact | EQUITY | Nov 17, 2026, 11:11 PM UTC
Technology Outage Wave Reaches US Government, Trump Says
The headline reports that a technology outage wave has reached the US government. The White House says there is no evidence
M impact | EQUITY | Nov 17, 2026, 11:03 PM UTC
Oppenheimer Sees Zscaler Fiscal Q1 Revenue Exceeding Guidance and Consensus
Oppenheimer projects Zscaler’s fiscal first-quarter revenue will exceed management guidance and analyst consensus ahead of the earnings release.
M impact | EQUITY | Nov 17, 2026, 11:03 PM UTC